Drug Profile
Research programme: factor X/Xa variants - Gyre Therapeutics
Alternative Names: CB FXa; CB-1965a; Factor XaLatest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Catalyst Biosciences
- Developer Gyre Therapeutics
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haemophilia; Haemorrhage
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 28 Dec 2021 No recent reports of development identified for preclinical development in Haemophilia in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Haemorrhage in USA